While the preclinical rationale for the addition of PD-1 axis ICB to hypomethylating therapy for the treatment myeloid malignancies is strong,21–24 the clinical evidence base for improved efficacy is lacking. This evidence concerns the gene PDCD1 and myeloid neoplasm.